|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 8,147,867: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 8,147,867, granted on April 3, 2012, to Vertex Pharmaceuticals, Inc., pertains to a novel class of small-molecule compounds intended for the treatment of cystic fibrosis (CF) by modulating the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This patent is significant within the landscape of CF therapeutics, particularly for its claims surrounding CFTR potentiators. This report examines the patent's scope, claims, and its positioning within the broader patent landscape to inform stakeholders about its strategic value, potential overlaps, and competitive landscape.
What is the Scope of Patent 8,147,867?
Background and Purpose
The patent focuses on pyrazolo[1,5-a]pyrimidine derivatives that function as CFTR potentiators. These compounds are designed to enhance the function of mutant CFTR proteins, particularly the F508del mutation, which accounts for approximately 70% of CF cases globally.
Patent Classification and US Patent Data
- Primary US Class: 514/230 (Drug or Medicinal Preparation containing Organic Compound)
- International Patent Classification (IPC): A61K 31/137 (Medicinal preparations containing organic active ingredients, specifically for lung diseases)
- Publication Date: March 29, 2011 (application publication), with patent grant on April 3, 2012.
Patent Assignee: Vertex Pharmaceuticals, Inc.
Patent Families & Related Applications:
This patent is part of a patent family involved in CFTR modulator development, with related patents focusing on combination therapies and second-generation compounds.
What Are the Key Claims of Patent 8,147,867?
Claim 1: Composition of Matter
- Broadest claim:
A compound of the formula (structure reference), or a pharmaceutically acceptable salt, solvate, or prodrug thereof.
- Encompasses a broad class of pyrazolo[1,5-a]pyrimidine derivatives with specific substitutions at defined positions.
Claim 2-10: Specific Embodiments
- Specific substitutions: Variations at positions R1, R2, R3, R4, R5, R6, defining the central structure's chemical diversity.
- Substituent specifics: Alkyl groups, halogens, hydroxyl, amino groups, etc., to optimize activity and pharmacokinetic profiles.
Claim 11: Pharmacological Use
- Use of the claimed compounds for modulating CFTR activity to treat conditions like cystic fibrosis.
Claim 12-20: Methods of Synthesis
- Outlines chemical synthesis routes, providing broad coverage of methods to produce the compounds.
Claims Scope Analysis:
| Claim Type |
Scope |
Limitations |
| Composition of matter |
Broad, covering entire chemical class |
Dependent on specific structural definitions |
| Use claims |
Specific to CFTR modulation and CF treatment |
Tied to the compound class described in composition claims |
| Method of synthesis |
Provides scope for manufacturing techniques |
Usually secondary, but protects synthesis methods |
Legal Priority & Validity:
The patent's claims are rooted in robust chemical novelty and inventive step, validated through patent examination reports citing prior art references such as existing CFTR modulators.
Patent Landscape Analysis
Dominant Players & Overlapping Patents
| Entity |
Main Patents / Focus Areas |
Relevance to 8,147,867 |
| Vertex Pharmaceuticals |
Extensive portfolio on CFTR modulators (e.g., ivacaftor, lumacaftor, tezacaftor) |
Fundamental inventor and assignee |
| AbbVie |
Developing CFTR modulator combinations |
Potential competition; overlaps in claims |
| Proteostasis Therapeutics |
Focused on CFTR correction and potentiation |
Complementary patent filings |
| Cystic Fibrosis Foundation |
Licensing and collaborating on CFTR therapies |
Licensing influence, no direct patents |
Recent Patent Applications & Trends
- Increasing filings on second-generation CFTR modulators and combination therapies to improve efficacy and address residual mutations.
- Patent filings increasingly focus on personalized medicine approaches, targeting specific CFTR mutations.
Major Patent Clusters
- Pyrazolopyrimidine derivatives—core class of compound in 8,147,867.
- Potentiator-related patents—claims covering compounds that enhance CFTR gating function.
- Combination Therapy Patents—targeting dual or multi-component treatments.
Deep Dive: Comparative Analysis of Related Compounds and Claims
| Patent / Article |
Focus |
Similarities with 8,147,867 |
Differences / Improvements |
| US Patent 8,568,806 (Vertex) |
CFTR potentiators, including pyrazolopyrimidines |
Similar core structure, expanded scope for substituted derivatives |
Broader claims on specific substituents |
| WO2018168512A1 (Vertex) |
Combination CFTR modulators, including ivacaftor |
Focus on combination therapies |
Focus on drug combinations rather than single compounds |
| Academic Literature |
Structure-activity relationships (SAR) |
Chemical backbone similar, SAR insights on substitutions |
Academic publications often cover narrower compound scope |
Implication:
The patent stands as a core foundational patent for a class of CFTR potentiators with extensive coverage, forming the basis for subsequent claims and development efforts.
Legal and Commercial Significance
- Patent Strength: The broad composition claims and method claims provide robust protection for Vertex’s CFTR potentiator pipeline, limiting generic competition on core compounds.
- Expiry Date & Market Impact: The patent is set to expire in 2030–2032, depending on application adjustments and possible patent term extensions (35 U.S.C. § 154).
- Licensing & Litigation: Vertex actively defends its patent rights; competitors have faced legal challenges around similar compounds, e.g., in invalidity and non-infringement suits.
FAQs
1. What is the primary innovation claimed by U.S. Patent 8,147,867?
It claims a novel class of pyrazolopyrimidine derivatives functioning as CFTR potentiators, specifically tailored for improving chloride transport in CF patients.
2. How does the scope of claims affect generic drug competition?
The broad chemical class claims significantly delay generic entry for compounds falling within the patent’s scope, especially for formulations that use the claimed derivatives.
3. Are there prior patents that challenge the novelty of 8,147,867?
Examination reports cite prior art related to CFTR modulators, but the specific pyrazolopyrimidine derivatives with the claimed substitutions are considered novel and inventive.
4. How does this patent relate to other CFTR modulator patents?
It provides a foundational chemical scaffold that underpins many subsequent patents focused on potassium channel gating and combination therapies.
5. What is the patent landscape outlook for CFTR potentiators?
The landscape is highly active, with ongoing patent filings on newer compounds, especially targeting cystic fibrosis mutations resistant to earlier drugs like ivacaftor.
Key Takeaways
- U.S. Patent 8,147,867 grants broad protection over a class of pyrazolopyrimidine compounds for CFTR potentiation, directly impacting the CF therapeutic space.
- Its claims encompass both the chemical compositions and their use in treating cystic fibrosis, forming a critical defensive barrier for Vertex Pharmaceuticals.
- The patent landscape includes various overlapping and subsequent filings aimed at refining and expanding the scope of CFTR modulators, with several players competing in this innovative domain.
- Strategic licensing, legal enforcement, and ongoing R&D are crucial to maintaining competitiveness over the patent life span.
- Future outlook indicates increased patent activity around multi-mechanistic CFTR therapies, personalized medicine, and next-generation compounds.
References
- U.S. Patent No. 8,147,867. (2012).
- Examiners’ reports and related patent documentation from USPTO.
- Literature on CFTR modulators and cystic fibrosis therapies (e.g., Zaire et al., 2013).
- Patent landscape reports from patent analytics firms (e.g., IPlytics, IAM).
- Vertex’s patent filings and public disclosures on CFTR modulators.
This report provides a comprehensive overview intended to inform research, development, licensing, and litigation strategies around U.S. Patent 8,147,867 and its broader patent landscape.
More… ↓
⤷ Start Trial
|
